# Easy to understand reports facilitate treatment options.



## **TOPA Diagnostics**

351 East Rolling Oaks Drive, Suite 100 Thousand Oaks, CA 91361 805-373-8582 CLIA Number 05D1022855

#### Directors

Wayne M. Schultheis, M.D. Edward I Blackman M.D. Regina Singson, M.D. Jianming J. Yin, M.D. Danielle E. Westfall, M.D.

# ADDENDUM FINE NEEDLE ASPIRATION REPORT

PATIENT:	PATIENT, YOUR	PATH #:	TF00-00001
D.O.B.	01/01/1946 AGE: 67 yrs SEX:	F DATE COLLECTED:	01/01/2000
PHYSICIAN:	Code Doctor, M.D.	DATE RECEIVED:	01/01/2000
COPY TO:		DATE REPORTED:	01/08/2013
LOCATION:	Physician Office		

### DIAGNOSIS:

LEFT THYROID, FINE NEEDLE ASPIRATION:


-Suspicious for follicular neoplasm, Hurthle cell type


## MICROSCOPIC DESCRIPTION:

Routine smears, ThinPrep, and cell block are cellular and demonstrate sheets of thyroid follicular cells with enlarged nuclei and prominent nucleoii. They have abundant granular cytoplasm. The findings are considered to be suspicious for a follicular neoplasm, Hurthle cell type. A differential consideration includes a dominant hyperplastic nodule with Hurthle cell metaplastic.

COMMENT: According to a recent consensus conference sponsored by the National Cancer Institute, a diagnosis of 
"suspicious for follicular neoplasm" is associated with a 15-30% risk of malignancy. Up to 35% will be non-neoplastic on 
exciston. Usual follow-up consists of surgical exciston (generally lobectiony). These are guidelines only: management should 
be based on the clinical situation of the individual patient. (Reference: Am J Clin Pathol 2009; 132: 655-657)

Based on the cytologic findings and reflex testing criteria, a sample will be submitted to Asuragen Laboratory for molecular testing. Results will be reported in an addendum report.





CLINICAL HISTORY:

ANATOMIC SITE AND PROCEDURE: Left thyroid, fine needle aspiration

GROSS DESCRIPTION:

5 slide(s). Red translucent needle washing in CytoLyt solution. Received 1 RNA retain tube. 1 Thin prep slide prepared. 1 cell block prepared.

Pathologist: Wayne Schultheis, M.D. Electronically Signed

ADDENDUM: RESULTS OF THYROID MOLECULAR TESTING INTERPRETATION:

No DNA mutations or RNA translocations detected (performed at Asuragen lab)

COMMENT: According to recent literature, the overall risk of malignancy for a cytology diagnosed as FN/SFN (follicular neoplasm / suspicious for follicular neoplasm) with no mutations identified is 14%.

Reference: Nikiforov, Y. et al JCEM (2009), 94(6): 2092-2098

Pathologist: Wayne Schultheis, M.D. Electronically Signed

DIAGNOSTICS

Our reports use standardized formatting and terminology with color images that make them easy to comprehend and foster patient-physician communication.

351 Rolling Oaks Drive, Suite 100 Thousand Oaks, CA 91361

Phone: 805.373.8582 Fax: 805.373.0023

Answering Service: 805.378.7761

Email Client Services at: clientservice@topathology.com